While Cytokinetics Inc has underperformed by -0.39%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CYTK rose by 59.89%, with highs and lows ranging from $110.25 to $30.68, whereas the simple moving average fell by -16.95% in the last 200 days.
On August 13, 2024, Goldman Downgraded Cytokinetics Inc (NASDAQ: CYTK) to Neutral. A report published by UBS on January 24, 2024, Downgraded its rating to ‘Neutral’ for CYTK. Morgan Stanley also Downgraded CYTK shares as ‘Equal-Weight’, setting a target price of $90 on the company’s shares in a report dated January 05, 2024. Goldman Initiated an Buy rating on November 09, 2023, and assigned a price target of $50. B. Riley Securities initiated its ‘Buy’ rating for CYTK, as published in its report on November 07, 2023. SVB Securities’s report from August 15, 2023 suggests a price prediction of $58 for CYTK shares, giving the stock a ‘Outperform’ rating. BofA Securities also rated the stock as ‘Neutral’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Cytokinetics Inc (CYTK)
Further, the quarter-over-quarter decrease in sales is -71.28%, showing a negative trend in the upcoming months.
One of the most important indicators of Cytokinetics Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. Taking into account the quick ratio of the company, currently set at 10.39, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and CYTK is recording 1.19M average volume. On a monthly basis, the volatility of the stock is set at 3.23%, whereas on a weekly basis, it is put at 2.83%, with a loss of -3.26% over the past seven days. Furthermore, long-term investors anticipate a median target price of $81.62, showing growth from the present price of $51.31, which can serve as yet another indication of whether CYTK is worth investing in or should be passed over.
How Do You Analyze Cytokinetics Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 3.33%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 113.83% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
CYTK shares are owned by institutional investors to the tune of 113.83% at present.
